Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

Citations Over TimeTop 10% of 2019 papers

Abstract

Sonidegib demonstrated sustained efficacy and a manageable safety profile. The final BOLT results support sonidegib as a viable treatment option for laBCC and mBCC. What's already known about this topic? Basal cell carcinoma (BCC) is usually treatable with surgery or radiation therapy, but there are limited treatment options for patients with advanced BCC. Sonidegib, a hedgehog pathway inhibitor approved for the treatment of advanced BCC, demonstrated clinically relevant efficacy and manageable safety in prior analyses of the phase II randomized, double-blind BOLT study [Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment]. What does this study add? This final 42-month analysis of BOLT is the longest follow-up available for a hedgehog pathway inhibitor. Clinically relevant efficacy results were sustained from prior analyses, with objective response rates by central review of the approved 200-mg daily dose of 56% in locally advanced BCC and 8% in metastatic BCC. No new safety concerns were raised. The results confirmed sonidegib as a viable long-term treatment option for patients with advanced BCC.

Related Papers

• → Randomized Controlled Drug Trials on Very Elderly Subjects: Descriptive and Methodological Analysis of Trials Published Between 1990 and 2002 and Comparison With Trials on Adults(2005)36 cited
• → Practice and Educational Effects of a Simulated Randomized Controlled Trial for Acupuncture School Teachers(2010)
• → Randomized Controlled Trials for Creating Scientific Evidence of the Efficacy and Safety of Complementary and Alternative Medicine(2004)
• A compatision between one visit RCT and several visit RCT for cracked teeth.(2007)
• Basical Clinical Observation of Cracked Tooth with One visit RCT(2003)